What's William Petttit's mailing address?
William's mailing address filed with the SEC is C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO, CA, 92121.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Ligand Pharmaceuticals
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... y Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
What does Ligand Pharmaceuticals do?
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
What does Ligand Pharmaceuticals's logo look like?
Ligand Pharmaceuticals executives and stock owners
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:
-
John Higgins,
Chief Executive Officer, Director -
Matthew Foehr,
President, Chief Operating Officer -
Matthew Korenberg,
Chief Financial Officer, Executive Vice President - Finance -
Charles Berkman,
Senior Vice President, General Counsel, Secretary -
John L. Higgins,
CEO & Exec. Director -
Matthew W. Foehr,
Pres & COO -
Matthew E. Korenberg,
Exec. VP of Fin. & CFO -
Charles S. Berkman J.D.,
Sr. VP, Gen. Counsel & Sec. -
Charles S. Berkman,
Sr. VP, Gen. Counsel & Sec. -
Sarah Boyce,
Independent Director -
John Kozarich,
Non-Executive Independent Chairman of the Board -
Stephen Sabba,
Independent Director -
Jason Aryeh,
Independent Director -
Todd Davis,
Independent Director -
Sunil Patel,
Independent Director -
Nancy Gray,
Independent Director -
John Lamattina,
Independent Director -
Simon Latimer,
Head of Investor Relations -
Patrick Lucy,
Sr. VP & CBO Protein Expression Bus. -
Dr. Vincent D. Antle,
Sr. VP of Technical Operations & QA - Capitsol -
Dr. Keith Marschke,
Sr. VP of Biology & Scientific Affairs -
Audrey Warfield-Graham,
Sr. VP of HR -
Todd Pettingill,
Director of Corp. Devel. -
Patrick O'Brien,
Sr. VP of Investor Relations -
Jason Haas,
Director -
Corp Plc Elan,
10% owner -
Andres Negro Vilar,
Exe V-P, R & D, CSO -
Partners L P/Ilbiotechnolog...,
-
Bruce Peacock,
Director -
Zofia E Dziewanowska,
VP, Clinical Research -
Partners L P/Ilbiotechnolog...,
-
Melanie J Herman,
Director of Accounting -
Nishan M De Silva,
VP, Corporate Development -
David M Knott,
10% owner -
Syed Kazmi,
VP, Bus. Dev. & Strategic Plan -
Martin Meglasson,
V-P, Discovery Research -
Pharmaceuticals Inc Ligand,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Steven J Burakoff,
Director -
Brigette Roberts,
Director -
Partners L P/Ilbiotechnolog...,
-
John P Sharp,
VP Finance and CFO -
Daniel S Loeb,
Director -
Michael A Rocca,
Director -
John Groom,
Director -
Taylor Crouch,
Sr. V-P, Ops & Pres. Int'l -
Partners L P/Ilbiotechnolog...,
-
Jeffrey R Perry,
Director -
Alexander D Cross,
Director -
William A Petttit,
Sr. V-P, HR and Administration -
Paul V Maier,
Sr. V-P, CFO -
Warner R Broaddus,
V-P, Gen. Counsel & Secy. -
Elizabeth M Greetham,
Director -
Henry F Blissenbach,
Director -
Irving S Johnson,
Director -
Carl C Peck,
Director -
Eric S Groves,
V-P, Project Management -
Giambattista Aliprandi,
Sr. VP, Tech., Sup & Intl Oper -
James J Litalien,
Sr. V-P, Reg Affairs & Comp. -
David E Robinson,
President & CEO -
Tod Mertes,
V-P, Controller & Treasurer -
Jennifer R. Cochran,
-
Octavio Espinoza,
Chief Financial Officer -
Martine Zimmermann,
Director -
Andrew Reardon,
CLO & Secretary